Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Twist Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Twist Bioscience's regulatory disclosures and financial reporting.
Adam Laponis filed a Form 144 notice to sell 3,000 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of 120000.00. The securities to be sold were acquired via restricted stock vesting from the issuer on three dates: 267 shares on 10/29/2025, 784 shares on 11/20/2025, and 1,949 shares on 01/08/2026, all as compensation. The filing notes that 61,148,026 shares of this class were outstanding.
Over the prior three months, Adam Laponis sold additional common shares: 5,517 shares on 10/30/2025 for gross proceeds of 173,478.20, 887 shares on 11/21/2025 for 23,508.60, and 2,738 shares on 01/09/2026 for 96,544.34. The notice includes a representation that the seller is not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Twist Bioscience Corporation furnished a current report to share preliminary, unaudited revenue results for its first quarter of fiscal 2026, covering the period ended December 31, 2025. The company announced these early revenue figures in a press release dated January 12, 2026, which is included as Exhibit 99.1. Twist notes that these revenue expectations are preliminary and may change after it completes its internal control, review, and audit procedures, so the final numbers in its quarterly financial statements could differ materially. The company also states that this information is being furnished, not filed, which limits how it is treated under securities law.
Adam Laponis has filed a notice of proposed sale of common stock under Rule 144. The filing covers a planned sale of 2,738 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of $96,544.34, when approximately 61,148,026 shares were outstanding and the shares are expected to be sold around 01/09/2026 on NASDAQ.
The 2,738 shares were acquired on 01/08/2026 via restricted stock vesting from the issuer as compensation. Over the prior three months, the same seller reported additional sales of common stock, including 2,517 shares for gross proceeds of $82,864.17, 5,517 shares for $173,478.20, and 887 shares for $23,508.60.
Twist Bioscience Corp (TWST) reported an insider transaction by its Senior Vice President, Chief Legal Officer & Corporate Secretary. On 11/21/2025, the reporting person sold 757 shares of Twist Bioscience common stock at a price of $26.5035 per share. After this transaction, the insider beneficially owned 145,402 shares directly.
The company explains that these shares were sold solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units. The sale was executed under the issuer’s equity incentive plan using a mandated “sell to cover” arrangement, meaning the transaction did not represent a discretionary trade or a change in the insider’s investment view.
Twist Bioscience Corp (TWST) reported an insider transaction by its President and COO on a Form 4. On 11/21/2025, the officer sold 1,776 shares of common stock at a price of $26.5035 per share. After this transaction, the officer beneficially owned 332,883 shares directly.
The company explains that these shares were sold solely to cover tax withholding obligations tied to the vesting of restricted stock units. The sale was mandated under the company’s equity incentive plans as a "sell to cover" transaction and is described as not a discretionary trade by the reporting person.
Twist Bioscience Corp (TWST) reported a small insider transaction by its Senior Vice President of Human Resources, Paula Green. On 11/21/2025, Green sold 598 shares of common stock at a price of $26.5035 per share. After this transaction, she beneficially owned 167,789 shares directly.
The company explains that the sale was made to cover tax withholding obligations triggered by the vesting of Restricted Stock Units. These transactions are described as mandated under Twist Bioscience’s equity incentive plans through a “sell to cover” election, meaning they are not discretionary trades initiated by the executive for portfolio reasons.
Twist Bioscience Corporation's Chief Financial Officer reported an automatic sale of company stock to cover taxes. On 11/21/2025, the reporting person sold 887 shares of common stock at a price of $26.5035 per share. The filing explains that these shares were sold under a mandatory "sell to cover" arrangement tied to the vesting of Restricted Stock Units, meaning the transaction was not a discretionary trade. After this tax-related sale, the officer beneficially owned 142,769 shares of Twist Bioscience common stock in direct ownership.
Twist Bioscience Corp (TWST) reported an insider transaction by its Chief Executive Officer and director, Emily M. Leproust. On 11/21/2025, she disposed of 2,663 shares of common stock at a price of $26.5035 per share in a sale coded "S." This sale was made to cover tax withholding obligations triggered by the vesting of restricted stock units, and is described as a mandatory "sell to cover" under the company’s equity incentive plans rather than a discretionary trade.
Following this transaction, Leproust beneficially owned 878,173 shares of common stock, held directly. She also holds several employee stock options with various exercise prices and vesting schedules, including performance stock options granted on September 1, 2020 that vested and became exercisable on December 19, 2022 after meeting specified performance criteria.
Twist Bioscience Corp (TWST) reported insider share sales by its Chief Accounting Officer. The reporting person sold 229 shares of common stock on 11/21/2025 at a price of $26.5035 per share and 822 shares on 11/24/2025 at a price of $28.7095 per share. After these transactions, the officer beneficially owned 66,143 shares of Twist Bioscience common stock in direct ownership.
According to the explanation, the 229 and 822 shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units under the company’s equity incentive plans, and the sales did not represent discretionary trades by the officer.
Twist Bioscience Corp (TWST) reported a new equity award to its Chief Executive Officer and director, Emily M. Leproust. On 11/18/2025, she received 146,914 shares of common stock in the form of restricted stock units at a reported price of $0 per share, increasing her directly held beneficial ownership to 880,836 common shares.
The RSU grant vests over four years, with 1/16 of the total vesting on each quarterly anniversary of November 20, 2025, subject to continued service. The filing also lists multiple outstanding employee stock options, including options with exercise prices of $8.82, $26.66, $23.33, and $67.85, covering hundreds of thousands of shares with expiration dates between 2027 and 2030. Some older options at $5.95 now show zero remaining shares.